Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Prometheus Biosciences, Inc. (RXDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/16/2023 8-K Resignation/termination of a director
Docs: "Amended and Restated Certificate of Incorporation of Prometheus Biosciences, Inc",
"Amended and Restated Bylaws of Prometheus Biosciences, Inc"
05/23/2023 8-K Other Events  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress - Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - SAN DIEGO, May 9, 2023 -- Prometheus Biosciences, Inc. , a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximatel..."
04/17/2023 8-K Quarterly results
02/28/2023 8-K Quarterly results
12/09/2022 8-K Quarterly results
12/07/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
10/03/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/11/2022 8-K Quarterly results
07/26/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/01/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/09/2022 8-K Quarterly results
12/13/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress -Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 -"
08/23/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy